Year |
Citation |
Score |
2016 |
Doerfler PA, Nayak S, Corti M, Morel L, Herzog RW, Byrne BJ. Targeted approaches to induce immune tolerance for Pompe disease therapy. Molecular Therapy. Methods & Clinical Development. 3: 15053. PMID 26858964 DOI: 10.1038/Mtm.2015.53 |
0.648 |
|
2016 |
Doerfler PA, Todd AG, Clément N, Falk DJ, Nayak S, Herzog RW, Byrne BJ. Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease. Human Gene Therapy. 27: 43-59. PMID 26603344 DOI: 10.1089/Hum.2015.103 |
0.668 |
|
2015 |
Doerfler PA, Nayak S, Herzog RW, Morel L, Byrne BJ. BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease. Clinical Immunology (Orlando, Fla.). 158: 140-7. PMID 25842186 DOI: 10.1016/J.Clim.2015.03.022 |
0.621 |
|
2015 |
Biswas M, Sarkar D, Kumar SR, Nayak S, Rogers GL, Markusic DM, Liao G, Terhorst C, Herzog RW. Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg. Blood. 125: 2937-47. PMID 25833958 DOI: 10.1182/Blood-2014-09-599266 |
0.639 |
|
2015 |
Biswas M, Sarkar D, Nayak S, Kumar SR, Rogers GL, Markusic DM, Liao G, Terhorst C, Herzog RW. 293. Optimal In Vivo Treg Induction and Suppression of Immune Responses By Synergistic Use of Rapamycin and FLT3 Ligand Molecular Therapy. 23: S118. DOI: 10.1016/S1525-0016(16)33902-8 |
0.679 |
|
2014 |
Corti M, Elder M, Falk D, Lawson L, Smith B, Nayak S, Conlon T, Clément N, Erger K, Lavassani E, Green M, Doerfler P, Herzog R, Byrne B. B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study. Molecular Therapy. Methods & Clinical Development. 1. PMID 25541616 DOI: 10.1038/Mtm.2014.33 |
0.651 |
|
2014 |
Nayak S, Doerfler PA, Porvasnik SL, Cloutier DD, Khanna R, Valenzano KJ, Herzog RW, Byrne BJ. Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent. Plos One. 9: e98336. PMID 24897114 DOI: 10.1371/Journal.Pone.0098336 |
0.63 |
|
2014 |
Elmallah MK, Falk DJ, Nayak S, Federico RA, Sandhu MS, Poirier A, Byrne BJ, Fuller DD. Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 702-12. PMID 24336173 DOI: 10.1038/Mt.2013.282 |
0.399 |
|
2014 |
Nayak S, Doerfler PA, Porvasnik SL, Cloutier DD, Khanna R, Valenzano KJ, Herzog RW, Byrne BJ. Antibody responses to varying doses of rhGAA in null mutation (n = 6) or P545L mutant mice (n = 5). Plos One. DOI: 10.1371/Journal.Pone.0098336.G003 |
0.537 |
|
2014 |
Doerfler PA, Kelley JS, Nayak S, Lawson LA, Byrne BJ. Pharmacological chaperones prevent the precipitation of rhGAA by anti-GAA antibodies during enzyme replacement therapy Molecular Genetics and Metabolism. 111. DOI: 10.1016/J.Ymgme.2013.12.073 |
0.387 |
|
2013 |
Markusic DM, Hoffman BE, Perrin GQ, Nayak S, Wang X, LoDuca PA, High KA, Herzog RW. Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. Embo Molecular Medicine. 5: 1698-709. PMID 24106230 DOI: 10.1002/Emmm.201302859 |
0.716 |
|
2013 |
Elder ME, Nayak S, Collins SW, Lawson LA, Kelley JS, Herzog RW, Modica RF, Lew J, Lawrence RM, Byrne BJ. B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. The Journal of Pediatrics. 163: 847-54.e1. PMID 23601496 DOI: 10.1016/J.Jpeds.2013.03.002 |
0.584 |
|
2012 |
Nayak S, Sivakumar R, Cao O, Daniell H, Byrne BJ, Herzog RW. Mapping the T helper cell response to acid α-glucosidase in Pompe mice. Molecular Genetics and Metabolism. 106: 189-95. PMID 22494547 DOI: 10.1016/J.Ymgme.2012.03.009 |
0.66 |
|
2012 |
Nayak S, Porvasnik S, Kelley J, Lee N, Byrne B. High Dose Rituximab Pretreatment in a New Human cd20-GAA−/− Mouse Model Causes Complete B-Cell Depletion and Reduction in Effector and Memory T-Cell Activation Molecular Genetics and Metabolism. 105: S48. DOI: 10.1016/J.Ymgme.2011.11.120 |
0.388 |
|
2011 |
Nayak S, Sarkar D, Perrin GQ, Moghimi B, Hoffman BE, Zhou S, Byrne BJ, Herzog RW. Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B. Frontiers in Microbiology. 2: 244. PMID 22279442 DOI: 10.3389/Fmicb.2011.00244 |
0.71 |
|
2011 |
Moghimi B, Sack BK, Nayak S, Markusic DM, Mah CS, Herzog RW. Induction of tolerance to factor VIII by transient co-administration with rapamycin. Journal of Thrombosis and Haemostasis : Jth. 9: 1524-33. PMID 21585650 DOI: 10.1111/J.1538-7836.2011.04351.X |
0.717 |
|
2011 |
Byrne BJ, Falk DJ, Pacak CA, Nayak S, Herzog RW, Elder ME, Collins SW, Conlon TJ, Clement N, Cleaver BD, Cloutier DA, Porvasnik SL, Islam S, Elmallah MK, Martin A, et al. Pompe disease gene therapy. Human Molecular Genetics. 20: R61-8. PMID 21518733 DOI: 10.1093/Hmg/Ddr174 |
0.561 |
|
2011 |
Nayak S, Kelley J, Falk L, Lawson L, Harfe K, Collins S, Wasserfall C, Atkinson M, Elder M, Byrne B. Immune modulation in early onset Pompe disease Molecular Genetics and Metabolism. 102: S31-S32. DOI: 10.1016/J.Ymgme.2010.11.107 |
0.34 |
|
2010 |
Liao G, Nayak S, Regueiro JR, Berger SB, Detre C, Romero X, de Waal Malefyt R, Chatila TA, Herzog RW, Terhorst C. GITR engagement preferentially enhances proliferation of functionally competent CD4+CD25+FoxP3+ regulatory T cells. International Immunology. 22: 259-70. PMID 20139172 DOI: 10.1093/Intimm/Dxq001 |
0.638 |
|
2010 |
Nayak S, Herzog RW. Progress and prospects: Immune responses to viral vectors Gene Therapy. 17: 295-304. PMID 19907498 DOI: 10.1038/Gt.2009.148 |
0.637 |
|
2010 |
Nayak S, Moghimi B, Herzog RW. Strategies to Prevent or Reverse Immune Responses Against Factor In Gene Replacement for Hemophilia B. Blood. 116: 3761-3761. DOI: 10.1182/Blood.V116.21.3761.3761 |
0.719 |
|
2010 |
Markusic D, Nayak S, Herzog RW. Humoral and Anaphylactic Responses to Factor IX In Murine Hemophilia B Are Genotype Dependent and Can Be Reversed by Hepatic Gene Transfer Blood. 116: 2202-2202. DOI: 10.1182/Blood.V116.21.2202.2202 |
0.674 |
|
2009 |
Martino AT, Nayak S, Hoffman BE, Cooper M, Liao G, Markusic DM, Byrne BJ, Terhorst C, Herzog RW. Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity. Plos One. 4: e6376. PMID 19652717 DOI: 10.1371/Journal.Pone.0006376 |
0.632 |
|
2009 |
Cao O, Hoffman BE, Moghimi B, Nayak S, Cooper M, Zhou S, Ertl HC, High KA, Herzog RW. Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1733-42. PMID 19603001 DOI: 10.1038/Mt.2009.159 |
0.722 |
|
2009 |
Nayak S, Cao O, Hoffman BE, Cooper M, Zhou S, Atkinson MA, Herzog RW. Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells Journal of Thrombosis and Haemostasis. 7: 1523-1532. PMID 19583824 DOI: 10.1111/J.1538-7836.2009.03548.X |
0.682 |
|
2009 |
Cooper M, Nayak S, Hoffman BE, Terhorst C, Cao O, Herzog RW. Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer. Human Gene Therapy. 20: 767-76. PMID 19309290 DOI: 10.1089/Hum.2008.161 |
0.662 |
|
2008 |
Nayak S, Hoffman B, Cooper M, Atkinson M, Cao O, Herzog RW. A Prophylactic Protocol for the Prevention of Inhibitor Formation in Gene Therapy for Hemophilia B by Shifting the Balance from An Effector to a Regulatory T Cell Response Blood. 112: 3531-3531. DOI: 10.1182/Blood.V112.11.3531.3531 |
0.644 |
|
2007 |
Cao O, Dobrzynski E, Wang L, Nayak S, Mingle B, Terhorst C, Herzog RW. Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood. 110: 1132-40. PMID 17438084 DOI: 10.1182/Blood-2007-02-073304 |
0.642 |
|
2006 |
Cao O, Wang L, Nayak S, Herzog RW. Regulatory CD4+CD25+ T Cells Are Required for Tolerance Induction to Factor IX by In Vivo Gene Transfer. Blood. 108: 452-452. DOI: 10.1182/Blood.V108.11.452.452 |
0.626 |
|
Low-probability matches (unlikely to be authored by this person) |
2013 |
Kamarajugadda S, Cai Q, Chen H, Nayak S, Zhu J, He M, Jin Y, Zhang Y, Ai L, Martin SS, Tan M, Lu J. Manganese superoxide dismutase promotes anoikis resistance and tumor metastasis. Cell Death & Disease. 4: e504. PMID 23429290 DOI: 10.1038/Cddis.2013.20 |
0.271 |
|
2012 |
Kamarajugadda S, Stemboroski L, Cai Q, Simpson NE, Nayak S, Tan M, Lu J. Glucose oxidation modulates anoikis and tumor metastasis Molecular and Cellular Biology. 32: 1893-1907. PMID 22431524 DOI: 10.1128/Mcb.06248-11 |
0.261 |
|
2019 |
Nayak S, Cross M, Brooks S, Bible P, Jiang K, Dell'Orso S, Gutierrez-Cruz G, Naz F, Sun H, Morasso M. 312 Epigenetic modules governing skin epidermal homeostasis Journal of Investigative Dermatology. 139: S54. DOI: 10.1016/J.JID.2019.03.388 |
0.03 |
|
Hide low-probability matches. |